A new method to evaluate spontaneous platelet aggregation in type 2 diabetes by Cellfacts

Area of Science:

• Hematology
• Diabetology
• Biomedical Engineering

Background:

• Diabetes mellitus is associated with altered platelet functional activities.
• Increased spontaneous platelet aggregation (SPA) and release of platelet-derived microparticles are observed in diabetic patients.
• Platelet-derived microparticles may play a role in hemostasis, coagulation, and thrombotic diseases.

Purpose of the Study:

• To introduce a novel method for evaluating SPA and platelet-derived microparticle release.
• To assess the utility of the Cellfacts analyzer for platelet function analysis.
• To investigate the role of platelet-activating factor (PAF) and the effects of vitamin E and a PAF antagonist (WEB 2086-BS) on platelet activity in type 2 diabetes.

Main Methods:

• Utilized the Cellfacts analyzer, employing electrical sensing flow impedance, to measure particle and cell size in conductive fluid.
• Employed platelet-rich plasma (PRP) from type 2 diabetes patients.
• Evaluated the impact of PAF, vitamin E, and WEB 2086-BS on SPA and microparticle release.

Main Results:

• The Cellfacts analyzer demonstrated efficacy in detecting alterations in platelet aggregation and microparticle release.
• The study assessed the influence of PAF and its antagonist on platelet activity in diabetes.
• Vitamin E and WEB 2086-BS effects on platelet function were measured.

Conclusions:

• The Cellfacts analyzer provides a simple and rapid tool for assessing platelet status in patients with functional platelet alterations.
• This method can be used to monitor the pharmacological treatment effects on SPA and microparticle release.
• The findings highlight the potential of the Cellfacts analyzer in clinical settings for managing diabetic patients with platelet dysfunction.